Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 06, 2023 07:20 ET | Source: ZyVersa Therapeutics

ZyVersa Therapeutics Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100’s Rationale for Targeting ASC to Inhibit Multiple Inflammasome Pathways

AIM2 and NLRP3 inflammasome activation leads to development of atherosclerotic lesions in diabetic mice.